NCT04317911

Catheter Ablation for Atrial Fibrillation in Preserved Ejection Fraction

Catheter Ablation for Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 102 (actual)
• Sponsor: University Hospital Heidelberg · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

Atrial fibrillation (AF) displays high prevalence in heart failure with preserved ejection fraction (HF-PEF) and compromises prognosis of affected patients. This study aims to assess catheter ablation (CA) for AF in patients with HF-PEF compared to AF-patients without systolic or diastolic dysfunction. Primary endpoints are freedom from AF and quality of life at 1 year. Furthermore, the study is designed to elucidate mechanistic characteristics distinguishing arrhythmic substrate and predicting AF-recurrence in patients with HF-PEF. For this purpose, left atrial concentrations of biomarkers for inflammation, fibrosis and neurohumoral activation are determined and hemodynamic measurements are performed periprocedurally. Information on benefit from CA in these patients is necessary for clinical decision making and mechanistic investigations may point to tailored approaches in order to increase therapeutic efficiency.

Conditions

• Atrial Fibrillation

Interventions

Type	Name	Description
OTHER	Catheter Ablation	Patients with preserved ejection fraction presenting for catheter ablation via of atrial fibrillation are included in this study and prospectively observed regarding arrhythmia-related, functional and biomarker-associated outcomes.

Timeline

• Start date: 2016-01-26
• Primary completion: 2021-09-01
• Completion: 2022-02-01
• First posted: 2020-03-23
• Last updated: 2022-10-27

Locations

1 site across 1 country: Germany